Subetta
ApprovedSmall molecule
Subetta is one of 59 small molecule programs targeting Impaired glucose tolerance. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
286 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1Amaryl
SanofiPhase 3
LY2605541
Eli LillyPhase 3
Subetta
MMateria Medica Holding
Approved
E.-Coli-Nissle
UUniversity of Oulu
Phase 3
Trulicity
Eli LillyPreclinical
Byetta
AstraZenecaPreclinical
Galvus
NovartisPreclinical
NOVOLIN R
Novo NordiskPreclinical
Edarbi
TakedaPreclinical
Paxil CR
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Diabetes Mellitus2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Subetta. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMateria Medica Holding